Business Context and Reporting Period
Company: Innate Pharma S.A.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Date: September 2, 2026
Principal Executive Office: Marseille, France
Context: This filing serves as a cover document for a press release dated September 2, 2026 (Exhibit 99.1). The text provided contains only the cover page and signature block; the actual content of the press release is not included in the source text.
Key Financial Metrics
The provided filing text does not contain specific financial data. Consequently, the following metrics are unavailable in this document:
- Revenue
- Profit/Loss
- Cash Flow
- Margins
- Debt Levels
- Liquidity Position
Material Changes
The filing text does not provide information regarding material changes versus prior comparable periods. The specific nature of the announcement in the referenced press release is not described in the cover document.
Guidance, Outlook, and Risks
No guidance, outlook, management commentary, risks, contingencies, or unusual items are detailed in the provided text. The document solely confirms the existence of a press release but does not summarize its contents.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) to understand the specific announcement made on September 2, 2026.
- Confirm if the press release contains updates on clinical trial results, regulatory approvals, or partnership agreements, which are typical for this issuer.
- Check subsequent filings (e.g., Form 20-F or 8-K) for detailed financial impacts related to the event announced in this 6-K.